PP
SBBP

PDT Partners’s Strongbridge Biopharma plc. SBBP Stock Holding History

PDT Partners’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-40,800
Closed -$183K – 523
2018
Q4 		$183K Hold
40,800
– – 0.01% 415
2018
Q3 		$198K Buy
40,800
+7,932
+24% +$40.6K 0.01% 434
2018
Q2 		$197K Buy
+32,868
New +$240K 0.01% 472

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PDT Partners's SBBP Position: Q1 2019 in Review

PDT Partners sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2019, closing a stake of 40,800 shares — an estimated $183K sold.

PDT Partners first reported a position in SBBP in Q2 2018 and held it in 3 quarters. The position peaked at $198K in Q3 2018. 51 funds tracked by Wall St. Rank hold SBBP as of Q1 2019.

  • PDT Partners reported no remaining Strongbridge Biopharma plc. position as of Q1 2019 after selling out during the quarter.
  • PDT Partners sold 40,800 Strongbridge Biopharma plc. shares in Q1 2019, an estimated $183K.
  • PDT Partners first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 3 quarters.
  • PDT Partners's Strongbridge Biopharma plc. position peaked at $198K in Q3 2018.
  • 51 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2019.

Based on PDT Partners's 13F filing for Q1 2019, filed 15 May 2019.